Novartis Exelon
Executive Summary
Firm clarifies that two-week or longer intervals between dose increases of Alzheimer's agent in postmarketing has resulted in "improved tolerability as evident from fewer GI complaints than seen in pivotal studies." The company previously said that rivastigmine postmarketing nausea/vomiting reports have been consistent with rates seen in clinical trials (1"The Pink Sheet" Feb. 5, p. 24)